- Article
Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
- Eva Juengel,
- Pascal Schnalke,
- Jochen Rutz,
- Sebastian Maxeiner,
- Felix K.-H. Chun and
- Roman A. Blaheta
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been es...